Article
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.
British journal of cancer - 1 Jun 2025
Bloem M, de Meza M M, van den Eertwegh A J M, Aarts M J B, van den Berkmortel F W P J, Blank C U, Blokx W A M, Boers-Sonderen M J, Bonenkamp J J, Boreel C D M, de Groot J W B, Haanen J B A G, Hospers G A P, Kapiteijn E, van Not O J, Piersma D, Rikhof B, Stevense-den Boer A M, van der Veldt A A M, Vreugdenhil G, Suijkerbuijk K P M, Wouters M W J M
Abstract excerpt
BACKGROUND: Adjuvant BRAF/MEK inhibitors (BRAF/MEK) and anti-PD-1 therapy have become the standard care in resected stage III/IV melanoma. A head-to-head clinical trial comparison is lacking. METHODS: All stage III BRAF-mutant melanoma patients who received adjuvant BRAF/MEK or anti-PD-1 (2018-2022) were included from the Dutch Melanoma Treatment Registry. Propensity score matching (PSM) was used to compare 1-...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.